GGrantIndex
Sort

23,748 grants matching melanoma

CANCER AND LEUKEMIA GROUP B

$105,261
Rhode Island Hospital (Providence, Ri) · U10 · FY2000 · CA

Core B: Pathology Core

$105,214
Meenhard Herlyn · Wistar Institute · P01 · FY2016 · CA

Core B: Pathology Core

$105,201
Meenhard Herlyn · Wistar Institute · P01 · FY2017 · CA

An integrated approach to melanoma metastasis and therapy resistance: effects of age-related changes in the ECM and the biomechanics of the skin

$105,092
Ashani T Weeraratna · Johns Hopkins University · R01 · FY2021 · CA

Characterization of Cancer Transcriptomes using Next Generation Sequencing

$105,068
Christopher A Maher · University Of Michigan At Ann Arbor · K99 · FY2011 · CA

Reviving cancer immune surveillance with CD4 T cell help

$105,021
Michael Clavon Brown · Duke University · K99 · FY2021 · CA

Adaptive regulation of cancer cell fate following oncogene inhibition

$105,000
Mohammad Fallahi-Sichani · University Of Virginia · R00 · FY2019 · CA

Eastern Cooperative Oncology Group

$104,956
Michael B Atkins · Beth Israel Deaconess Medical Center · U10 · FY2010 · CA

Identifying Microenvironmental Factors Regulating Melanoma Promotion and Immune Evasion

$104,944
Hyeongsun Moon · University Of California At Davis · K01 · FY2021 · OD

Identifying Microenvironmental Factors Regulating Melanoma Promotion and Immune Evasion

$104,944
Hyeongsun Moon · University Of California At Davis · K01 · FY2022 · OD

Cushing's Disease Whole Exome Sequencing Study

$104,918
James Mills · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2020 · HD

TUMOR VACCINES FOR THE TREATMENT OF ORAL MELANOMA

$104,897
University Of Wisconsin Madison · R01 · FY2001 · DE

Immunologic & Genetic Determinants of Outcome & Response to IFN-a2b Therapy

$104,848
John Munn Kirkwood · University Of Pittsburgh At Pittsburgh · P50 · FY2008 · CA

Toward safe, systemic immunotherapies for treatment of metastatic disease: Developing dendritic cell-biased immunomodulators with precise control over magnitude and timing of immune stimulation

$104,840
Sachin Bhagchandani · Yale University · K00 · FY2024 · CA

CUTANEOUS ONCOLOGY

$104,777
University Of Texas Md Anderson Can Ctr · K24 · FY2002 · CA

Consolidated Basic Cancer Research Program

$104,776
Dario C. Altieri · Wistar Institute · P30 · FY2020 · CA

PREPHASE I GENE/IMMUNE THERAPY OF MALIGNANT BRAIN TUMOR

$104,590
Rush University Medical Center · R01 · FY2000 · CA

Genomic Instability in Melanoma Pathogenesis

$104,557
University Of Pennsylvania · K08 · FY2002 · CA

Melanoma in p16INK4a and p19ARF Deficient Mice

$104,504
Dana-Farber Cancer Institute · K08 · FY2002 · CA

Hypoxia induces SHMT2 to regulate cellular redox and epigenetics

$104,417
Jiangbin Ye · Sloan-Kettering Inst Can Research · K99 · FY2015 · CA

Hypoxia induces SHMT2 to regulate cellular redox and epigenetics

$104,417
Jiangbin Ye · Sloan-Kettering Inst Can Research · K99 · FY2016 · CA

02 - Experimental Therapeutics

$104,387
Narendra Wajapeyee · University Of Alabama At Birmingham · P30 · FY2024 · CA

02 - Experimental Therapeutics

$104,385
Eddy Yang · University Of Alabama At Birmingham · P30 · FY2022 · CA

02 - Experimental Therapeutics

$104,385
Eddy Yang · University Of Alabama At Birmingham · P30 · FY2023 · CA

Mayo Comprehensive Cancer Center Grant

$104,369
Robert B. Diasio · Mayo Clinic Rochester · P30 · FY2010 · CA